Comparative Pharmacology
Head-to-head clinical analysis: ACCRUFER versus FERRLECIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCRUFER versus FERRLECIT.
ACCRUFER vs FERRLECIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACCRUFER (ferric maltol) is an oral iron replacement therapy. Ferric iron is complexed with maltol, which enhances absorption. Once absorbed, iron is utilized for hemoglobin synthesis and erythropoiesis.
Ferric carboxymaltose, a polynuclear iron(III)-hydroxide carbohydrate complex, provides a source of iron for hemoglobin synthesis and erythropoiesis. The iron is released to endogenous iron transport proteins, such as transferrin, and stored as ferritin or hemosiderin.
170 mg (1 tablet) orally twice daily (340 mg total daily dose) for adults with iron deficiency anemia, taken on an empty stomach at least 1 hour before or 2 hours after meals.
125 mg elemental iron (5 mL) intravenously over 1-5 minutes or as infusion over 15-30 minutes, repeated as needed based on iron deficiency.
None Documented
None Documented
20 hours (prolonged in hepatic impairment)
Sodium ferric gluconate has a terminal half-life of approximately 1 hour for the intact complex. However, after dissociation, iron is rapidly cleared from plasma with a half-life of about 6 hours. The clinical context: the short half-life minimizes free iron toxicity but requires frequent dosing for iron replacement.
Renal 65% (as unchanged drug), fecal 35%
Iron is not excreted renally; elimination is primarily through fecal loss of unabsorbed iron (approximately 80-90% of orally administered iron) and minor desquamation of mucosal cells. After IV administration, iron is incorporated into hemoglobin and storage pools; minimal urinary excretion (<1%). Biliary excretion of iron is negligible.
Category C
Category C
Iron Replacement
Iron Replacement